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Abstract: Breast cancer is the most frequent cause of cancer‐related deaths among women 
worldwide. It is classified into four major molecular subtypes. Triple‐negative breast cancers 
(TNBCs), a subgroup of breast cancer, are defined by the absence of estrogen and progesterone 
receptors and the lack of HER‐2 expression; this subgroup accounts for ~15% of all breast cancers 
and exhibits the most aggressive metastatic behavior. Currently, very limited targeted therapies 
exist for the treatment of patients with TNBCs. On the other hand, it is important to highlight that 
knowledge of the molecular biology of breast cancer has recently changed the decision‐making 
process regarding the course of cancer therapies. Thus, a number of new techniques, such as gene 
profiling and sequencing, proteomics, and microRNA analysis have been used to explore human 
breast carcinogenesis and metastasis including TNBC, which consequently could lead to new 
therapies. Nevertheless, based on evidence thus far, genomics profiles (gene and miRNA) can differ 
from one geographic location to another as well as in different ethnic groups. This review provides 
a comprehensive and updated information on the genomics profile alterations associated with 
TNBC pathogenesis associated with different ethnic backgrounds. 




Breast cancer is the most frequently diagnosed cancer in women worldwide [1]. In 2012, breast 
cancer accounted for 25% of the prevalent cancer cases worldwide [2]. In developing countries, it is 
the most common cause of death (14.3%), whereas in developed countries it is the second leading 
cause of cancer mortality (15.4%) [1].  
Various environmental factors contribute to a woman′s risk of developing breast cancer. 
Increasing age, menarche, high hormonal levels, null‐parity, tobacco use, and obesity [3–9] are risk 
factors and account for 47% of the breast cancer (BC) cases [10]. Approximately 5–10% of the cases 
are attributed to genetic factors that include BRCA (BRCA1 and BRCA2) mutations [11–13]. BRCA1/2 
are autosomal dominant and tumor suppressor genes present on chromosomes 17 and 13, 
respectively, and are mutated in approximately 30–40% of familial BC cases [14]. 
On the other hand, oncogenes and tumor suppressor genes are involved in the tumorigenesis of 
sporadic BC [15]. While most of cancer‐related deaths are a result of complications from its metastatic 
form [16,17]; however, the mechanisms underlying malignant progression in BC are yet to be 
elucidated. Research has identified numerous genetic changes in malignant tumors, although the 
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frequency of different gene alterations is quite low [18]. Recently, “significantly mutated genes” 
(SMGs) were identified in the onset of malignant transformation [19] and few of them encode for 
proteins interacting with BRCA1/2, while others act through different pathways including TP53, 
PTEN, CHEK2, ATM and PALB2 [20]. Mutations in these genes are suspected to elevate the risk of BC 
development. 
Various prognostic and predictive factors are studied in BC, including estrogen/progesterone 
receptors (ER/PR) status and HER-2/neu gene amplification [21,22]. Steroid receptor status, HER‐
2/neu status, nodal status, tumor size, and grade have been used for several years [23], however, none 
of these factors are reliable predictors of disease outcome. 
Gene expression profiling in BC started in the mid‐1990s, this technique allowed classification 
of BC into subtypes via hierarchical clustering of several gene expression profiles of human breast 
tumors [24–26]. BC was first classified into its intrinsic molecular subtypes luminal, Her2, basal‐like 
and normal breast using cDNA microarrays by Perou and colleagues (2000) [27]. Following this 
study, another study differentiated molecular subtypes linked with different prognosis and further 
subdivided the luminal group into luminal A and luminal B [28]. Analysis between the subtypes 
showed the basal‐like and the Her2+ subtypes have the shortest overall survival times and relapse‐
free survival in comparison with the estrogen‐receptor positive groups [29]. The study showed that 
the basal‐like subtype potentially represented a different clinical entity linked with shorter survival 
and a high frequency of TP53 mutations. Genome‐wide expression arrays of tumors demonstrated 
the tumor biology; range in patterns reflected the biological diversity [29]. Based on these subtypes, 
an Expert Consensus established four clinic‐pathological definitions, recommending therapeutic 
strategies for each group [30]. Further research revealed additional subtypes such as a claudin‐low 
BC, a subtype of basal‐like BC [31]. However, a larger cohort of breast tumors needs to be assessed 
along with comprehensive clinical information to identify clinical phenotypes including resistance 
and sensitivity to specific therapies, invasiveness, or metastatic potential [29]. 
In this review, we will focus on the role of microarray molecular profiling (genes and 
microRNAs) as a prognostic, diagnostic as well as a therapeutic tool for the most aggressive BC 
phenotype in different ethnic groups, which is triple negative BC. 
2. Triple Negative Breast Cancer (TNBC) 
Triple negative breast cancer (TNBC) is a subgroup of BC, representing 12–17% of all BCs [32]. 
TNBCs have a comparatively lower expression of the three receptors: ER, PR and HER‐2/neu in 
comparison with normal tissue as well as other types of BC. It affects more frequently young patients, 
and is represented by advanced stage, higher proliferative index (measured by mitotic account or Ki‐
67 proliferative index), higher histologic grade, and significantly higher metastatic rates [33–36]. 
TNBCs have a higher prevalence in a distinct group or population [13]; for example, in African‐
American women the prevalence of TNBCs is very high [37]. TNBC was found to be prevalent in 
young women of African descent [38]. Environmental as well as genetic factors are known to impact 
the age of onset and subtype frequency in different populations [38]. In TNBCs, metastatic rates are 
high to visceral organs [39,40]; in addition, cerebral metastasis is more common [17,41–43]. De‐novo 
metastasis plays a key role in cancer mortality with racial/ethnic disparities in the site, frequency, and 
associated survival [44]. Racial/ethnic differences in BC can partially be due to variations in the 
biological aggressiveness of TNBC in African women as compared with other racial/ethnic groups 
[45]. Recent studies in BC patients showed that non‐Hispanic blacks largely had metastasis to the 
bone, brain, or liver, while Hispanics were less likely to have metastasis to the liver in comparison to 
the non‐Hispanic Whites [44].  
Sub‐classification of TNBCs have been attempted based on several biomarkers including 
epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), c‐kit and basal 
cytokeratins (e.g., CK5/6, CK14, CK17), TP53, TOP-2A, Ki67, Cox‐2 and heat shock protein 90 [36]. 
Nevertheless, all TNBCs have a poor clinical prognosis and special pathological characteristics 
compared to other subtypes of BC. The overall 5‐year survival rate for TNBC is 50–60% [37,46,47], 
with a lower likelihood of developing recurrent tumor over the following 5‐years in these patients 
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[37,48]. TNBCs are associated with a higher rate of local recurrence during the first three years after 
treatment and a high five‐year mortality rate compared with other subtypes of BC [49]. 
Systemic treatment for breast cancer includes the use of cytotoxic, hormonal, and 
immunotherapeutic agents. To date, cytotoxic chemotherapy is the only approved treatment option 
for TNBC [36,50,51]. Systemic agents are effective at the beginning of therapy in the majority (90%) 
of primary and approximately half of metastatic breast cancer cases [52]. However, after a period of 
time, tumor progression occurs; resistance to therapy is common leading to treatment failure and 
death in more than 90% of patients with advanced/metastatic disease [52]. Metastasis is a multifarious 
process in which a primary solid tumor plagues the adjacent tissue and then spreads to the 
neighboring as well as distant parts of the body [53]. During tumor progression, the cells undergo 
epithelial‐to‐mesenchymal transition (EMT), thus enhancing cell invasion and commencing the 
process of metastasis, one of the hallmarks of cancer [54] (Figure 1).  
 
Figure 1. Schematic outline showing normal and abnormal genes and miRNA profiles of normal 
mammary and breast cancer. It is evident that there are variations in gene expressions and miRNA 
profiles from normal to non‐invasive and invasive cancer, in which epithelial‐mesenchymal transition 
(EMT) is the main hallmark. Thus, combined gene and miRNA profiles can be used as novel 
Biomarkers and therapy targets for each step of cancer progression. However, it is important to 
highlight that Gene and miRNA profiles can differ from one geographic location to another as well 
as between different ethnic groups. 
Generally, breast cancer cells metastasize to the bone, liver, lung and brain [16]. However, there 
is no efficient targeted therapy available presently for the treatment of patients with TNBCs, 
especially in its metastatic form [55]. 
Knowledge of molecular biology in breast cancer has recently introduced new‐targeted 
therapies using cDNA microarray, proteomics, next‐generation sequencing (NGS) and miRNA 
technologies. Among the novel treatment agents for breast cancer are poly (ADP‐ribose) polymerase 
(PARP) inhibitors, angiogenesis inhibitors, EGFR‐targeted agents, and src kinase inhibitors [56]. 
Other favorable molecular targets include the androgen receptor (AR), insulin‐like growth factor 
receptor (IGFR), protein kinase B (AKT), mTOR [57], PI3K [58] and cyclin‐dependent kinases [59].  
The following sections will present a comprehensive review about gene expression profiling 
performed on TNBC to identify potential biomarkers related to cancer progression and metastasis in 
TNBC patients. 
  
Normal Gene & miRNA Profile
Abnormal Gene & miRNA Profile
Cancer Cell 
Abnormal Gene & miRNA Profile
Cell Invasion & Metastasis
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3. Gene Expression Profiling of TNBC 
Microarray technologies have transformed research, allowing high‐throughput whole‐genome 
expression profiling and helped cancer scientists including oncologist to provide insight in a single 
assay about several diseases as well as create a molecular profile of tumor progression [24,25]. 
Although on a morphological level TNBC and basal‐like breast cancer (BLBC) are comparatively 
similar in relation to large tumor size, high histologic grade, and substantial metastatic potential 
[60,61], gene expression profiling classified around 70% of TNBC samples as basal‐like [62]. 
Molecular heterogeneity of TNBC has been recently well characterized at gene expression 
profiling level. An earlier investigation identified six molecular subtypes of TNBC including basal‐
like 1, basal‐like 2, immunomodulatory, mesenchymal‐like, mesenchymal stem‐like, and luminal 
androgen receptor (LAR) subtype [63]. Nevertheless, molecular subtyping of TNBC by gene 
expression profiling revealed three subtypes, namely luminal androgen receptor, basal‐like with low 
immune response and high M2‐like macrophages and, basal‐enriched with high immune response 
and low M2‐like macrophages) [64]; which could provide insight for treatment of TNBC. 
Both basal‐like subtypes (basal‐like 1 and basal‐like 2) are affected by molecular alterations in 
cell‐cycle, DNA machinery, cell proliferation, glycolysis and gluconeogenesis. These TNBC subtypes 
were found to be sensitive to cisplatin and PARP inhibitors. However, while, the basal‐like 1 subtype 
displays elevated levels of Ki‐67 as well as genes involved in cell division and DNA‐damage (ATR, 
BRCA, Myc, NRAS), basal‐like 2 subtype is characterized by high levels of EGFR, MET, EPHA2 and 
TP53 genes [57].  
On the other hand, the immunomodulatory subtype was shown to overexpress genes involved 
in regulating immune cell signaling such as JAK1/2, STAT1/4, IRF1/7/8 and TNF. Recently, research 
showed stimulation of the immune signaling pathways including TNF enhanced PD‐L1 expression 
[65]. PD‐L1 overexpression is common in basal breast cancers and is linked with high T‐cell cytotoxic 
immune response, better survival and response to chemotherapy [65,66]. The gene expression profile 
of this subtype was found to be similar to medullary breast cancer [67,68], indicating a good 
prognosis and a favorable response to both adjuvant and neoadjuvant therapy [69].  
Gene expression profile of the other two subtypes (mesenchymal and mesenchymal stem‐like) 
resemble the chemo‐resistant metaplastic breast cancer. The mesenchymal subtype shows elevated 
levels of genes involved in EMT, cell motility, cellular proliferation and differentiation (Wnt, ALK, 
TGF-β). On the other hand, the mesenchymal stem‐like subtype expresses genes involved in 
angiogenesis, growth factor pathways along with those regulating cellular proliferation and 
differentiation (EGFR, PDGFR, ERK1/2, VEGFR2) [57]. Moreover, the mesenchymal stem‐like subtype 
shows low‐levels of claudins-3,4,7; a characteristic similar to the claudin‐low subtype [31]. 
Furthermore, both subtypes (mesenchymal and mesenchymal stem‐like) may respond well to 
PI3K/mTOR inhibitors as well as abl/src inhibitor (dasatinib) [57].  
The last known subtype, luminal androgen receptor (LAR), is found to overlap with the 
molecular apocrine group (“molecular apocrine breast cancer”/MABC) and is enriched in genes 
regulating hormone signaling, in particular androgen signaling and synthesis (AR, FOXA1, KRT18, 
XBP1) [70]. This subtype displays shorter relapse‐free survival and plausible therapeutic targets 
include flutamide, enzalutamide, bicalutamide [71]. However, the LAR/MABC may not be equivalent 
to invasive apocrine carcinoma as defined by cancer morphology and steroid receptor profile [72]. 
Research showed that the basal‐like 2 subtype has worst survival, whereas, LAR has the best 
survival rates. Although, molecular subtypes of TNBC are associated with differences in survival and 
can potentially contribute in treatment selection, the association of patient race or ethnicity with 
subtypes of TNBC and clinical outcome still lie nascent. A recent study showed that more than half 
(53%) of Hispanic women had a significantly higher proportion of basal‐like 2 subtype, whereas 
Asians had a lower proportion (19%) and a higher proportion of LAR (38%) compared to the average 
proportion across all groups [73]. On the other hand, Asian women had a better overall survival 
compared to other ethnic groups [73]. These variations across racial and ethnic groups in the subtypes 
may explain differences in their outcomes. Determining TNBC subtypes can help in understanding 
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the heterogeneity of TNBCs and can pave the way for developing subtype‐specific therapies and 
better predictors of TNBC prognosis for all races and ethnicities. 
The Cancer Genome Atlas Research Network (TCGA) used genomic DNA copy number arrays, 
exome sequencing, mRNA arrays and miRNA sequencing in 76 TNBC patients and identified several 
mutated genes, the most common being TP53 (80%), PIK3CA (9%), MLL3 (5%), AFF2 (4%), RB1 (4%), 
and PTEN (1%) [58]. Whole genome sequencing analysis of 65 TNBC cases detected six SMGs, of 
which TP53 was the most frequently mutated gene. Moreover, clonal frequency analysis identified 
somatic mutations in TP53, PIK3CA and PTEN dominant in the majority of TNBCs [74]. Several other 
studies have also confirmed that TP53 gene as the most commonly mutated gene (65–80%) in TNBC 
[58,74]; these mutations result in genetic instability and cytogenetic alterations [75]. Research showed 
that a loss of TP53 resulted in enhanced metastasis and worse overall survival [76]. Furthermore, the 
presence of mutations in TP53 can be a predictor of chemo‐resistance in breast cancer [77,78] 
including neoadjuvant chemotherapy; however, larger prospective studies are needed to further 
analyze its role as a potential therapeutic target in breast cancer as well as other cancers [79]. The 
other most common gene involved in breast cancer including TNBC is BRCA1/2; more than half of 
the hereditary TNBC cases (80%) carry mutation in BRCA1, while germ‐line mutation in BRCA1 
occurs in 15% of TNBC cases [80,81]. Patients lacking BRCA1/2 function are sensitive to platinum 
derivatives as well as PARP inhibitors [56]. Several investigations have identified and validated 
potential biomarkers of genomic instability as a response to platinum‐based therapy in TNBC [82].  
Recently, a tissue microarray study on African‐American women displayed a significant link 
between TNBC and loss of PTEN gene, a negative regulator of the PI3K pathway [83]. They also 
showed that a loss of PTEN activates the mTOR pathway resulting in a high cellular proliferation 
leading to a more aggressive cancer phenotype and progression [83]. The study implied mTOR 
inhibitors as potential therapeutic agents. Similar results were found using tissue microarray in 
Middle Eastern population, where loss of PTEN occurred at high frequency in TNBC and was 
associated with poor prognosis [84]; thus it can be used as a predictive factor for a poor clinical 
response of neoadjuvant chemotherapy in TNBC [85]. 
Moreover, African‐American women with breast cancer showed increased expression of p53, 
BRCA1, Aurora A, Aurora B and polo‐like kinase signaling networks in comparison with European 
women [38,86]. Additionally, incidence of germline BRCA1 mutations is relatively low in comparison 
with women of European descent [38]. Furthermore, compared with African Americans, non‐
Hispanic, non‐Jewish [87,88] and the Ashkenazi‐Jewish women [87] had higher rates of deleterious 
BRCA1 mutations. Similarly, less than 20% of African‐American women had germline mutations in 
comparison with Caucasian non‐Ashkenazi‐Jewish women with TNBC who had at least 50% rate of 
germline BRCA1 mutations [89], thus, indicating other underlying mechanisms for the onset of TNBC 
in African‐American women. Genes involved in the WNT–β‐catenin pathway were significantly 
deregulated in women of African origin compared with women of European descent, suggesting 
stimulation of the WNT–β‐catenin pathway in the development of the more aggressive phenotype of 
TNBC in women of African origin [38,90]. 
Furthermore, phosphatase INPP4B, a negative regulator of the PI3K pathway, was found to be 
lost in TNBC. Loss of INPP4B was linked with advanced tumor grade, larger tumor size, a loss of 
hormone receptors and aggressive tumors. Alterations in PIK3CA enhance the PI3K pathway and are 
present in around 10% of TNBC cases [91]. This data indicates frequent alterations in the 
PI3K/AKT/mTOR pathway in TNBC and are considered as potential therapeutic targets. INPP4B is a 
distinctive marker for human basal‐like carcinoma and can be a potential candidate for treatment 
using PI3K pathway inhibitors [92]. Nevertheless, initial clinical data from phase I trials using 
inhibitors did not show any substantial response rates when used as a single agent therapy [93]. A 
phase 2 clinical trial demonstrated that ipatasertib, an AKT inhibitor, improved the outcomes in a 
subset of patients with metastatic TNBC when combined with paclitaxel [94]. In addition, 
development of novel compounds with distinctive specificity and potency targeting different 
PI3K/AKT/mTOR components and related molecules are under process as they can provide a huge 
range of toxic profiles and immediate efficiency [94]. Research is now focusing on analyzing possible 
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inhibitors of PI3K/AKT/mTOR for treating TNBC alone or in combination with other drugs [95]. 
Moreover, drugs targeting other components of the pathway are being developed and include PDK1 
inhibitors, SHIP agonists, and heat shock protein inhibitors [93]. 
Another study identified six differentially expressed genes (IL32, PTX3, GATA3, TMEM158, 
ETS1 and MYBL1) in TNBC, which differentiated a subset of TNBC‐25 (25 TNBC samples) from other 
TNBCs, as well as TNBC from normal‐like, luminal A, luminal B and HER2 patient samples [96]. In 
TNBC patients in Mexico, a gene signature with 9 over‐expressed genes (PRKX/PRKY, UGT8, 
HMGA1, LPIN1, HAPLN3, FAM171A1, BCL141A, FOXC1 and ANKRD11) and 1 down‐regulated gene 
(ANX9) involved in metabolism was discovered using microarray gene expression profiling, 
however, further research needs to be conducted in different populations and geographical areas [97]. 
In parallel, gene expression analysis along with the Gene Set Enrichment Analysis (GSEA) was used 
to identify the Yin (upregulated pathway in cancer) and Yang (down‐regulated pathway in cancer) 
in TNBC samples. The analysis showed that while, FOXM1 was upregulated, PPARα was 
downregulated in TNBC; the Yin and Yang pathways allowed categorization of TNBC further into 
six sub‐groups (C1–C6) each having different clinical outcomes, thus providing insight into TNBC 
heterogeneity; however, further validation for prognosis and treatment is required [98]. Blocking of 
FOXM1 induces apoptosis and reduces invasiveness and VEGF expression of TNBC cells; impeding 
FOXM1 along with cisplatin treatment shows synergistic effect. FOXM1 can serve as a potential target 
for anticancer activity as well as overcoming cisplatin resistance in TNBC [99,100]. Another 
transcription factor, FOXA1 can play a role in cellular differentiation; thus, overexpression of FOXA1 
is associated with a favorable prognosis [101]. 
Gene expression analysis along with pathway enrichment analysis identified pathways and 
genes (SOX8, AR, C9orf152, NRK and RAB30) involved in the onset of TNBC that could be developed 
as potential therapeutic targets [102]. Two‐step genetic screening in TNBC showed loss of ADNP, 
AP2B1, TOMM70A and ZNF326 in nude mice, of which further research on ZNF326, showed that it 
regulated tumor cell growth through effects on RNA splicing, epithelial‐mesenchymal transition, and 
cancer stem‐cell self‐renewal. This study identified novel tumor suppressors in TNBC that can be 
used as potential targets for therapeutic approach [103]. Loss of expression of these genes lead to 
cellular migration and invasion (Table 2) and is associated with patient survival [103]. 
In a Japanese study conducted by Komatsu et al., DNA microarray identified 104 genes that 
were significantly over‐expressed in TNBC and included cancer specific kinases (NEK2, PBK and 
MELK) as well as genes involved in mitosis (ASPM and CENPK), which can be developed as 
molecular targets [104]. Deregulation of ASPM, CENPK, MELK, NEK2, PBK genes play a role in 
tumorigenesis and cell cycle regulation; since they induce programmed cell death, therefore, they can 
be targeted as novel treatment in TNBCs [104]. On the other hand, androgen receptor (AR) regulates 
cellular proliferation and differentiation; its presence can indicate a good prognosis [105]. Treatment 
of both LAR and non‐LAR TNBC subtypes using AR inhibitors enzalutamide and bicalutamide in 
in‐vitro and xenograft models showed elevated apoptotic rate and loss of proliferation, anchorage‐
independent growth, migration, and invasion [106,107]. While, the TBCRC011 study, using 
bicalutamide in AR‐positive patients showed a relatively weak response, with a 6‐month clinical 
benefit rate of 19% [108], a MDV3100‐11 study using enzalutamide showed higher clinical activity, 
with a 6‐month clinical benefit rate of 28% [109]. Further research aims on explicating the underlying 
mechanisms of AR therapy resistance and how to classify patients based on the outcome. Further 
investigations involve use of CYP17 inhibitors or a combination of AR inhibitors with CDK4/CDK6 
inhibitors, PI3K inhibitors or neoadjuvant chemotherapy [110]. AR is an easily detectable marker and 
can aid in classifying TNBC patients who will derive the least clinical benefit from standard 
chemotherapy. AR‐dependent TNBC patients could gain from targeted therapy based on AR 
antagonists alone or in combination with other chemotherapeutic agents [111]. 
Furthermore, in China, potential biomarkers (HORMAD1, ELF5, KLK6, GABRP, AGR2, AGR3, 
ANKRD30A, NME5 and CYP4Z3P) were identified using gene microarray to characterize TNBC 
[112]. Anterior Gradient (AGR)-2 and -3 are involved in cellular migration, transformation, metastasis 
and apoptosis. While overexpression of AGR2 indicates bad prognosis, overexpression of AGR3 can 
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be used as a serum‐based biomarker for detecting cancer at early stages [113]. In another study in 
China, microarray analysis revealed differential gene expression profiles between breast cancer 
subtypes among which COL4A2, BMF, DUSP1, FOXA1 and MLPH were identified as potential 
candidate gene targets in TNBCs [114]. Another major study using transcriptome microarrays 
established a combined mRNA‐long non‐coding (lnc) RNA signature based on the mRNA species for 
FCGR1A, RSAD2, CHRDL1 and the lncRNA species for HIF1A-AS2 and AK124454. They further 
demonstrated that HIF1A-AS2 and AK124454 enhanced cellular growth and invasion in TNBC cells 
and contributed to a paclitaxel resistance [115]. Another gene expression analysis study was 
performed to identify prognostic markers for TNBC; the study found that overexpression of EOMES, 
RASGRP1 and SOD2 were associated with better overall survival, while, loss of FA2H and GSPT1 
were linked with better overall survival in TNBC [116].  
Furthermore, based on a microarray study, other little‐known genes in TNBC were identified; 
two upregulated (PROM1 and KLK6) and seven downregulated (KRT18, GPR160, CMBL, AGR3, 
CREB3L4, CRIP1 and SDR16C5) genes that could serve as plausible biomarkers [112]. Moreover, 
KRT18 is used to determine poor response to chemotherapy [112]. 
Bioinformatics analysis in TNBC showed the presence of genes (AURKA, BIRC5, BUB1B, BUB1, 
CCNB1, CDK1, KIF11, MAD2L1, NDC80 and PLK1) involved in cellular proliferation; CCNB1 
displayed overexpression and was significantly associated with poor prognosis in TNBC [117]. 
Although these studies were carried out in South Asian population, different genes were found to be 
involved in the pathogenesis of TNBC and these could be used as promising therapeutic targets. 
Table 1 summarizes list of genes identified in TNBC by gene expression profiling in different 
geographic regions and Table 2 gives a brief overview of the biological functions of some identified 
genes in BC. 
Table 1. List of Genes involved in Progression of Triple‐Negative Breast Cancer Identified by Gene 
Expression Profiling. 
Gene Country Method Reference 
PTEN USA, Middle East Tissue microarray [83,84] 
PIK3CA USA Reverse phase protein array [91] 
ADNP, AP2B1, TOMM70A, ZNF326 USA Two‐step genetic screening [103] 
ANKRD11, BCL141A, FAM17IAI, 
FOXC1, HAPLN3, HMGT8, HMGA1, 
LPIN1, PRKX, PRKY, UGT8 
Mexico 






Gene enrichment analysis 
(GSEA) 
Gene expression analysis 
[98] 
SOX8, AR, C9/F152, EOMES, FA2H, 
GSPT1, NPK, RAB30, RASGRP1, SOD2 
China 
Gene enrichment analysis 
(GSEA) 
Gene expression analysis 
[102,116] 
BMF, COL4A2, DUSP1, FOXA1, 
FCGR1A, HIF1A-AS2, MLPH 
China Microarray analysis [114] 
RSAD2, AK124454 China Transcriptome microarrays [115] 
AGR2, AGR3, ANKRD30A, CMBL, 
CREB3L4, CRIP1, CYP4Z3P, ELF5, 
GABRP, GPR160, HORMAD1, KLK6, 
KRT18, NME5, PROM1, SDR16C5 




Bio‐informatics analysis [117] 
ASPM, CENPK, MELK, NEK2, PBK Japan DNA microarray [104] 
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Table 2. List of Genes and their role in TNBC. 





















Cell Cycle Regulation 
CCNB1 










On the other hand, the initial commercial gene expression signature of BC is MammaPrint® 
(Agendia, Amsterdam, The Netherlands), measures mRNA of 70 gene expressions as an assay with 
prognostic value in breast cancer patients. It has been validated for patients with stages I/II and 
negative or either one or three positive lymph nodes. This gene signature stratifies patients into low‐
and high‐risk groups and identifies patients who can avoid adjuvant chemotherapy [123,124]. 
Although the stratification is beneficial for ER+ breast cancers, it lacks advantage for ER− cancers, 
thus making it limited to a substantial proportion of patients [125]. MammaPrint ® has been approved 
by the Food and Drug Administration (FDA) and has been recommended by several guidelines such 
as St. Gallen′s International Oncology Guidelines for the treatment of early stage breast cancer. 
The Oncotype DX® test (Genomic Health, Redwood City, CA, USA) measures 21 gene‐
expressions (15 tested genes associated with breast cancer plus 6 reference genes). Oncotype DX® test 
analyzes genes associated with the ER status, proliferating genes, Her2‐related genes as well as genes 
related to cancer invasion. This test provides information whether chemotherapy treatment will be 
beneficial [126], measures the recurrence risk and classifies them into low‐risk, intermediate risk or 
high risk groups (the Recurrence score is given as a number between 0 and 100) [126]. The Oncotype 
DX® test may also be utilized for ductal carcinoma in situ (DCIS), the most common form of non‐
invasive breast carcinoma. This test did not require the FDA approval but has been recommended by 
various authority bodies and guidelines [127]. 
The Prediction Analysis of Microarray (PAM) algorithm to a 50‐gene set (Prosigna®, Stanford, 
CA, USA) is a 50‐gene signature, with an algorithm for the intrinsic molecular classification of breast 
cancer. It was introduced to improve immunohistochemical and microarray classification. The 
PAM50 groups breast cancer patients into luminal A, luminal B, HER2 and basal‐like [128]. Based on 
PAM50 score, a phase II trial in metastatic TNBC treated with platinum monotherapy showed an 
increased trend toward objective response rate in basal versus non‐basal TNBC, however results were 
not statistically significant [129]. Another study had a neoadjuvant setting and involved pretreatment 
of tumor samples. The results showed and advantage in the addition of carboplatin in all PAM50 
subtypes, including non‐basal TNBCs [130]. These studies indicated the limited use of available 
PAM50 assay in managing several TNBC cases. This test is also validated to predict the risk of 
metastasis for the postmenopausal patients with ER+, HER2‐negative, early breast cancer with 
negative lymph nodes. 
The EndoPredict Test (provided by Myriad Genetics, Inc., Salt Lake City, UT, USA), is another 
genomic test utilized for patients with newly diagnosed, early‐stage (node negative), ER‐positive and 
HER2‐negative breast cancer. It includes 12 genes: Eight cancer related genes, three RNA reference 
genes and one DNA reference gene [131]. EndoPredict calculates a risk score called Endopredict 
score, which can be used with well‐established clinicopathologic variables in predicting patients’ 
outcome. Although the EndoPredict Test has not been routinely approved by the FDA, some 
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authorities such as ASCO suggested its use to assist in the decision‐making regarding adjuvant 
chemotherapy treatment in patients with early‐stage, ER–positive, and HER2‐negative breast cancer 
[131]. 
Breast Cancer Index (provided by BCI, Biotheranostics, Inc., San Diego, CA, USA) is based on 
the expression of five proliferation‐related genes (molecular grade index (MGI)). It gives the 2‐gene 
ratio HOXB13:IL17BR (H:I) in a linear model. The BCI was developed for the decision‐making of 
adjuvant hormonal therapy in postmenopausal women with early stage, ER‐positive BC [132]. 
As indicated, the TNBC subtype is highly heterogeneous and its classification is routinely based 
on immunohistochemical biomarkers and limited gene signatures (e.g., PAM50 and Lehmann’s 
system) [29,57]. Although, these are vital prognostic tools, they are frequently applicable to the 
luminal subtypes and their use as prognostic tools for TNBC has not been validated yet [133]. Hence, 
there is an urgent need to develop signatures to aid in the early diagnosis and better treatment 
stratification of the TNBC patients. Today, with the advancement of genomic techniques and assays, 
developing novel diagnostic and prognostic biomarkers provide further insights into possible 
therapeutic targets. 
In conclusion, it is evident that gene profiling of BC including TNBC in a specific population of 
different genetic background can play an important role in developing new biomarkers and gene 
targets for the management of different types of BC and especially TNBC (Figure 1). In addition, it is 
important to note that a recent AJCC TNM also incorporated the genomic assays discussed above 
into the current TNM staging system of BC (eighth edition published in 2017) [131]. However, none 
of the clinically validated gene expression assays has been approved or recommended for TNBC and 
HER2‐negative patients but for ER+ breast cancers. Therefore, further efforts should be made to 
accomplish this extremely important task and clinically validate gene expression assays for a more 
proper management of the patients with these aggressive cancers. 
In parallel, it is important to highlight that microRNA profiling can also be essential in the 
development and management of BC and especially TBNC (Figure 1) which is the topic of the 
following section.  
4. MicroRNAs (miRNAs) in TNBC 
MicroRNAs (miRNAs) belong to the class of small non‐coding RNA, measuring around 25nt in 
length. miRNAs have distinct functions at the post‐transcriptional level [134,135]. Since miRNAs are 
stable in whole blood, plasma, and serum, circulating miRNAs are being studied in healthy controls 
and BC patients as a potential diagnostic, predictive and prognostic biomarker for the development 
of therapeutic strategies [136]. 
miR‐30 expression is associated with ER and PR expression while miR‐213 and miR‐203 
expression are linked with tumor stage. In BC, loss of 29 miRNAs was identified when compared 
with normal breast tissues [137]. Experimental studies have demonstrated the role of miRNAs in the 
metastatic process, where few miRNAs are either significantly upregulated or downregulated [138]. 
A recent study on four ethnic groups identified differential expression of 9 miRNAs. In Nigerian 
patients, significantly higher levels of miR‐140‐5p, miR‐194 and miR‐423‐5p were seen in BC 
compared with other ethnic groups [139]. On the other hand, in Indian patients, miR‐101 was 
overexpressed in BCs [139]. Furthermore, in‐silico analysis of miR‐423‐5p showed that AC genotype 
was associated with Europeans; while, Asians and Africans displayed the CC and AA genotype, 
respectively [139]. Another study identified 33 previously undescribed miRNA variants, and 31 
miRNA containing variants to be differentially expressed between African and non‐African 
populations [140]. Furthermore, a 26‐miRNA panel differentiated TNBC between African American 
and non‐Hispanic White women; however, further validation is needed [141]. A study on Lebanese 
BC patients showed 21 dysregulated miRNAs and 4 miRNAs with different expression patterns in 
comparison with American patients; plausible cause for these variations could be age of diagnosis or 
ethnic variation affecting miRNA epigenetic regulation or sequence of miRNA precursors [142]. 
Nevertheless, variation in miRNA expression in BCs from different ethnic groups can indicate that 
specific genetic variants in miRNAs may affect breast cancer risk in these groups. 
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Various miRNAs were linked with EMT and the development of stem‐cell properties. These 
miRNAs included upregulated expression of miR‐10b, miR‐21, miR‐29, miR‐9, miR‐221/222, miR‐373 
as well as downregulated expression of miR‐145, miR‐199a‐5p, miR‐200 family, miR‐203, miR‐205 in 
TNBC [143,144]. In this regard, tristetraprolin, a target for miR‐29a, regulates EMT and metastasis in 
BC [145]. 
The miR‐200 family including miR‐200b, suppress cancer cell growth as well as EMT by 
targeting ZEB1/2, SIP1, BMI1 proteins and inhibiting PKCα [146–150]. The miR‐200 expression was 
lost in TNBC cells in comparison with other subtypes of breast cancer resulting in increased cellular 
migration and invasion [43,147,148]. In addition, a loss of miR‐200 family was observed in 
mesenchymal‐like TNBC human breast cancer cell lines including MDA‐MB‐231 [151,152]. The loss 
of miR‐206 in TNBC was shown to promote angiogenesis and invasion in both cell‐lines as well as 
tissue samples [153]. Recently, a study in breast cancer cell lines revealed miR‐199/miR‐214 as a 
cluster of miRNAs enhancing cellular motility and aggressiveness via proliferation and EMT [154]. 
A loss of miR‐214 increases the aggressiveness of TNBC via proliferation and EMT, as well as 
promotes cell growth by enhancing the PTEN‐PI3K\AKT signaling pathway. Alterations of miR‐10b, 
miR‐21, miR‐29, miR‐145, miR‐200 family, miR‐203, miR‐221/222 were found to be of prognostic value 
in TNBC patients [143]. A research study by Kim et al. (2011) analyzed the therapeutic effect of miR‐
145 against breast cancer and found that adenoviral construct of miR‐145 (Ad‐miR‐145) had the 
potential to inhibit cell growth and motility both in vitro and in vivo [155]. Furthermore, a combined 
treatment of Ad‐miR‐145 and 5‐FU showed a remarkable anti‐tumor activity when compared to 
treatment by 5‐FU alone [155]. 
Microarray analysis also revealed deregulation (loss) of miR‐205 in cells that undergo EMT in 
TNBC in response to TGF‐β [151,156]. MicroRNA expression profiling in TNBC samples revealed 
low miR‐205 indicating its tumor‐suppressive role [157]. P53‐stimulation leads to loss of miR‐205 in 
TNBC and its re‐expression significantly inhibits cell proliferation, cell cycle progression and tumor 
growth in vivo [156]. Research showed E2F1 and LAMC1, known regulators of cell cycle progression, 
adhesion, proliferation and migration as experimentally validated targets for miR‐205 [156]. 
Circulating miR‐21 distinguished patients with loco‐regional disease from those with metastases 
[158]. miR‐21 promotes metastasis of breast cancer cells by targeting PTEN, TIMP1, TIMP3, PDCD4 
[158] which in turn affects the PI3K/AKT/mTOR pathway [159]. In addition, miR‐21 sera levels are 
linked with TNBC phenotype and familial breast cancer along with lymph node metastasis and a 
higher Ki‐67 expression [160,161]. 
Using qPCR, miR‐190a, miR‐136‐5p, miR‐126‐5p, miR‐135b‐5p and miR‐182‐5p were linked with 
the pathogenesis of TNBC. MiR‐190a plays a tumor‐suppressor role preventing metastasis, growth 
and cell invasion by suppressing VEGF‐mediated tumor angiogenesis [162]. On the other hand, miR‐
135b family plays an oncogenic role regulating the cell cycle, and promoting TNBC cells invasiveness 
and migration by targeting TGF‐beta, WNT and ERBB pathways [163]. A few common genes under 
the regulation of miR‐135b include APC, KLF4, MAFB, CASR, PPP2R5C, SMAD5, LZTS1, MID1, 
MTCH2, ACVR1B, BMPR2, TGFBR1, IBSP, BGLAP, RUNX2 and, SP7 [162]. MiR‐34a/c is a tumor 
suppressor and induces apoptosis in TNBC cells [164,165]; loss of miR‐34a/c [164] and miR‐940 [166] 
in TNBC was linked with tumor progression and poor prognosis. 
A panel of several miRNAs were also significantly altered in TNBC, indicating their role as 
useful prognostic and therapeutic factors in TNBC [167–170]. While miR‐135b, miR‐105/93‐3p, miR‐
21, miR‐17‐5p, miR‐27a, miR‐95‐3p were attributed to the onset, progression and metastases of TNBC 
[163,171–175], another array of miRNAs unraveled to be linked with chemo‐resistance [170,176–178]. 
Thus, up‐regulation of miR‐155‐5p, miR‐21‐3p, miR‐181a‐5p, miR‐181b‐5p, miR‐183‐5p, miR‐105/93‐
3p and loss of miR‐181a, miR‐10b‐5p, miR‐451a, miR‐125b‐5p, miR‐31‐5p, miR‐195‐5p and miR‐200c 
were found to be highly associated with promoting chemo‐resistance [146,174,176,179–182]. MiR‐27a 
plays a role in the onset and progression of tumor cells in TNBC and can predict response to 
radiotherapy and serve as a prognostic marker [175]. Presently, investigations aim to identify miRNA 
clusters associated with chemoresistance and to help pave the way for the development of more 
efficient therapies. 
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MiRNA profiling by next‐generation sequencing (NGS) in TNBCs revealed different expression 
patterns of miRNAs, of which three miRNAs (miR‐224‐5p, miR‐375 and miR‐205‐5p) can be used to 
categorize cancers based on their proliferation, invasion and metastasis. Six miRNAs (high let‐7d‐3p, 
miR‐203b‐5p and miR‐324‐5p; low miR‐30a‐3p, miR‐30a‐5p and miR‐199a‐5p) were significantly 
related to decreased overall survival while 5 additional miRNAs (high let‐7d‐3p; low miR‐30a‐3p, 
miR‐30a‐5p, miR‐30c‐5p and miR‐128‐3p) were associated with decreased relapse‐free survival [173]. 
Another study demonstrated that loss of miR‐30a in TNBC, which suppresses cell invasion and 
metastasis of the tumor by directly targeting ROR1; miR‐30a is linked with higher histological grade 
and lymph node metastasis [183]. Moreover, sequencing identified that loss of miR‐4319 in TNBC 
and presence of miR‐4319 was shown to reduce malignant potential of TNBC cells as it suppresses 
the self‐renewal and formation of tumor spheres in TNBC through E2F2 as well as inhibits tumor 
initiation and metastasis [184]. Deep sequencing along with hierarchical clustering analysis exhibited 
25 miRNAs signature to distinguish TNBC from normal breast tissue [185]. Genome‐wide miRNA 
profiling showed a panel of 26 miRNAs to help distinguish TNBC in African‐American women from 
the Non‐Hispanic White patients [141]. 
Lack of miR‐603 resulted in high eEF2K expression followed by the onset and progression of 
TNBC [186]. Another miRNA, miR‐199a‐5p, was found to have a tumor suppressive role in TNBC. 
High levels of miR‐199a‐5p in vivo reduced cell motility and invasiveness as well as repressed tumor 
cell growth [187]. Tissue microarray analysis showed that loss of miR‐493 in TNBC patients can be 
linked with poor disease‐free survival, depicting its role as a prognostic factor in TNBC [188]. Using 
miRNA array analysis, miR‐211‐5p showed to block proliferation, invasion, migration and metastasis 
by targeting SETBP1; indicating a tumor suppressive role of miR‐211‐5p in TNBC; [189]. While, miR-
148a [190] and miR‐629‐3p [191] were identified as promoters of lung metastases; while, miR‐141 was 
identified as an enhancer of brain metastasis; suggesting their roles as biomarkers and latent targets 
of metastases [192]. 
Studies have also shown presence of upregulated miRNAs in TNBC. The miR‐10 family (miR‐
10a and miR‐10b) is involved in both the progression and metastasis of breast cancer [193]. MiR‐10b 
is one such group of miRNAs, highly elevated in TNBC cell lines MDA‐MB‐231 and SUM1315 
compared with normal mammary epithelial cells HMECS and MCF10A [194,195]. miR‐10b is 
significantly upregulated in metastatic breast cancer cells and initiates cell migration and invasion in 
murine xenograft model of breast cancer by targeting the HOXD10 gene along with E‐cadherin and 
Tiam1 [196–198]. MiR‐10b controls cell migration and invasion and regulates the expression of miR‐
9. MiR‐9 is upregulated in TNBC in comparison with the luminal and HER2‐enriched breast cancer 
subtypes [199] and stimulates cell motility and invasion ability by targeting E‐cadherin, activating 
the β‐catenin pathway and enhancing VEGF levels [195]. In TNBC, miR‐9 was linked with MYC 
amplification, higher tumor grade, as well as significant metastatic potential leading to poor outcome 
[195,200]. Moreover, elevated miR‐105/93‐3p enhances the Wnt/βcatenin signaling by 
downregulation of SFPR1 leading to chemo‐resistance and metastasis [174]. MiR‐221/222 [201], miR‐
761 [202] and miR‐373 [165,203,204] are frequently upregulated in TNBC. Research on metastatic 
samples showed an inverse correlation between miR‐373 and CD44; targeting of CD44 by miR‐
373/520 increases the migratory and invasive ability, both in vitro and in vivo. Clinical metastasis 
samples also showed an inverse correlation between miR‐373 and CD44 expression [204]. High levels 
of miR‐221/222 enhance drug resistance and promote EMT, invasion and cancer cell migration. 
Additionally, miR‐221/222 were also associated with advanced stage, tumor grade and negative 
hormone receptor status [201,205]. Among Indian women with TNBC, a miRNA signature of 6 
different miRNAs (miR‐21, miR‐221, miR‐210, miR‐195, miR‐145 and let‐7a) were associated with an 
advanced stage, higher tumor grade and negative hormone receptors [205]. 
miR‐21 is the principal miRNA linked with migration and invasion of breast cancer cells and 
hence plays a critical role in tumor progression and metastasis [206,207]. A report by Iorio et al. (2005) 
showed that along with miR‐125b, miR‐145 and miR‐155, miR‐21 is aberrantly expressed in human 
breast cancer [137]. Tropomyosin 1 (TPM1) has been discovered as a plausible target of miR‐21 [208]. 
While, miR‐21 is inversely associated with PTEN expression in BC [209], which is directly linked with 
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TGF‐β [210]. Overexpression of miR‐21 leads to an aggressive disease status along with higher tumor 
grade, negative hormone receptor status and ductal phenotype [210]. A recent investigation 
conducted in Saudi Arabia identified miR‐195 in the plasma of TNBC patients [211]. 
In summary, a large group of miRNAs has been reported to be implicated in TNBC initiation, 
progression and/or metastasis. These miRNAs can be differentiated based on their functional 
characterization in TNBC as tumor suppressors and oncogenes. They may also play both diagnostic 
and predictive roles. Therefore, we believe that miRNA represent as an important target in the 
management of BC including TNBCs, however, it is important to highlight that genetic backgrounds 
of different populations have to be carefully examined in order to identify specific miRNAs 
associated with populations of various ethnicities (Figure 1). 
Table 3 below summarizes key miRNAs with their expression levels and biological functions in 
TNBC. 
Table 3. List of miRNAs and their Roles in TNBC. 
Biological Functions 
miRNAs References 
Stimulate Inhibit  
Cell Proliferation 
miR‐155‐5p, miR‐199, miR‐










375, miR‐629‐3p, miR‐141, 
miR‐10b, miR‐105/miR‐93‐
3p, miR‐761, miR‐181a, 
miR‐181a‐5p, miR‐181b‐
5p, miR‐183‐5p 
miR‐190a, miR‐30a, miR‐4319, 









Cell Cycle Regulation miR‐135b, miR‐135b‐5p  [163,213] 
Cell Apoptosis miR‐31‐5p miR‐21, miR‐23p, miR‐27a 
[158,160,161,167,171,175
,205,212] 















Despite the array of miRNAs that have been suggested as plausible biomarkers, their use in 
clinical practice still remains nascent. One of the major reasons being the challenge in miRNA 
expression profiling; miRNAs are tiny molecules in which family members display a high degree of 
homology, and absolute miRNA concentrations in body fluids are relatively low [214]. There are 
several technological advances for using miRNAs as therapeutic tools for cancers. miRNA expression 
profiles are correlated with genetic subtype and isotype [215]. Biology and characteristic features of 
miRNAs have been studied among different cancers. Standardizing expression of down‐regulated 
miRNAs or overexpressed miRNAs can aid to re‐balance the expression of genes associated in 
oncogenesis and tumor progression; hence, targeting miRNAs may provide an important therapeutic 
strategy for human cancer [196,216]. On the other hand, blocking overexpressed miRNAs was 
accomplished using anti‐miRNA oligonucleotides (AMOs), which are complementary to miRNAs. 
While, generation of down‐regulated miRNAs were accomplished using expression systems that use 
viral or liposomal delivery systems for the vectors [217,218]. 
Various miRNAs are validated in preclinical tests and are now under further clinical 
investigation. In 2013, The first miRNA replacement therapy with MRX34—a liposome‐formulated 
miR‐34 mimic was carried out. This study underwent human clinical trials for patients with advanced 
or metastatic liver cancer by intravenous injection [219]. Moreover, to treat different solid carcinomas 
including lung and prostate cancer, let‐7 mimic was developed [220,221]. For hepatitis C, an 
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antagonist of miR‐122 was used and tested in phase II clinical trials [222]. Moreover, an investigation 
by Di Martino et al. [223] proved that either transient expression of miR‐34a synthetic mimics or 
lentivirus‐based stable enforced expression of miR‐34a, triggered growth inhibition and apoptosis in 
MM cells in vitro and in vivo without systemic toxicity. Blocking of miRNA‐21 using antisense 
oligonucleotides reduced growth of MCF7 cells by topotecan by around 40% [224]. Similarly, in lung 
cancer cell lines, inhibition by AG1478 reduced cellular growth [193,225,226]. Recently, MRG‐106, an 
LNA anti‐miR of miRNA‐155 entered clinical phase I evaluation. Inhibition of miRNA‐155 in 
lymphoma cells reduced proliferation in‐vitro [214]. However, there are several challenges including 
suboptimal delivery, low bioavailability or long‐term safety. Research is focusing presently on latent 
methods including nanoparticles, polymers and virus‐based approaches [227]. Nevertheless, and 
given the important role of miRNA profiling in personalized medicine, we believe that more studies 
are necessary to elucidate miRNA profile variations in relation with ethnicity. 
5. Conclusions 
In BC, gene‐expression‐based‐assays and the classification of patients have a robust clinical 
impact and help in individualized therapy and personalized cancer management [228]. Therefore, 
several gene expression‐based assays have been clinically validated and utilized for ER+ but not ER‐ 
BCs such as TNBC. 
Differential gene expression using microarray profiling on a subset of BC including TN from 
different geographical regions in comparison to a set of normal/benign breast tumors should be 
performed to further understand the underlying mechanisms of TNBCs. 
Numerous challenges hinder treatment of BC, particularly in TN subtype resulting in a high 
cancer mortality. Genetic markers of women from different ancestries that predispose them to TNBC 
have not been entirely elucidated. Therefore, biomarkers for TNBC prognosis of specific ethnicities 
are urgently needed since they can be used as predictive biomarkers as well as tools for targeted 
therapy in these populations. In short, discovering combined gene and miRNA signatures of TNBC 
in different populations and ethnicities could help identify new and specific gene targets for this 
subgroup of cancers and can be regarded as a fertile ground to accomplish a personalized medicine 
approach, which is the main objective of modern cancer treatment. 
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